142nd APHA Annual Meeting and Exposition

Annual Meeting Recordings are now available for purchase

Economic Impact of Fetal Alcohol Spectrum Disorders

142nd APHA Annual Meeting and Exposition (November 15 - November 19, 2014): http://www.apha.org/events-and-meetings/annual
Sunday, November 16, 2014

Dewan Raja, MBBS, MPHIL, MPH , Live Sciences, Palmer College of Chiropractic Florida, Port Orange, FL
Bahar Sultana, MBBBS , Live Sciences, Palmer College of Chiropractic Florida, Port Orange, FL
Fetal alcohol spectrum disorders are caused by the toxicity of alcohol that reaches the fetus via the placenta. Alcohol consumption during first trimester of pregnancy is the most critical period of teratogenic insult that increases the risk of physical, behavioral, and cognitive disorders. Fetal alcohol spectrum disorder is completely preventable although it is not easy to execute the prevention program. We conducted systemic review of literature related to the impact of social and economic costs of fetal alcohol spectrum disorders. In the United States the FASD cost $ 6-8 billion each year directly.Indirect costs are many times more than the direct costs.  The estimates of cost differ significantly among the literature because of variable research methodology and the period of research time. Alcohol intake during pregnancy is linked with a variety of expensive and adverse fetal outcomes, abstinence , mass health education, and perinatal counselling are  worthwhile public health objectives to prevent these disorders .

Learning Areas:

Advocacy for health and health education
Biostatistics, economics
Planning of health education strategies, interventions, and programs
Provision of health care to the public

Learning Objectives:
Discuss the economic impact of fetal alcohol spectrum disorder

Keyword(s): Alcohol Use, Birth Outcomes

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I am a medical doctor, an anatomist, and a public health specialist.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.